Status:
COMPLETED
Vascular Improvement With Olmesartan Medoxomil Study
Lead Sponsor:
Daiichi Sankyo
Conditions:
Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in...
Eligibility Criteria
Inclusion
- Male or female
- 18-75 years of age
- Mean seated diastolic BP 90-109 or mean seated systolic BP of 140-179
Exclusion
- Secondary hypertension
- Renal disease
- Diabetes mellitus
- Serum creatinine \>3.0 mg/dL
- Hemoglobin \<10 mg/dL (males) or \<9mg/dL (females)
- WBC count \<2000 cells/mL
- Platelet count \<100,000 cells/mL
- Either ALT \& AST \>2.5 x upper limit of normal
- BMI \>35 kg/m2
- TIA or cerebrovascular attack within 3 months of study entry
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00772499
Start Date
November 1 2002
End Date
July 1 2005
Last Update
October 15 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157